Bacterial & Viral Specimen Collection Market

The global bacterial & viral specimen collection market size was valued at USD 13.6 billion in 2019 and is projected to expand at a during the forecast period, 2021–2028. The growth of the market is attributed to the increase in demand for diagnostic testing for COVID-19. Major companies are working on the development of error-free laboratory-quality specimen collection, this in turn, is expected to drive the bacterial & viral specimen collection market.

Bacterial & viral specimen collection is widely adopted in the healthcare sector to identify or detect the presence of disease in a body of individuals. To successfully diagnose the disease, the specimen collection is conducted in a sterilized manner to ensure that the sample should not get contaminant in the given environment. Therefore, using this specimen collection equipment requires to follow certain standard of quality checking and efficiency level before launching the devices in the market.

Bacterial and viral infections are becoming more common phenomenon and widely spread across the world due to their highly contagious nature. The impact of climate change and the reduced immunity of aging population that are key factors responsible for a wide prevalence of several viral infections across the globe. Globalization aggravates the situation, as microorganisms that are originated from a specific area can be spread easily to one area mix with humans contact from other parts of the world. This is shown by the latest COVID-19 pandemic.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing companies collaborating and investing heavily with other companies to develop affordable and innovate in specimen collection equipment are expected to drive the growth of the market.
• Growing public and private funding from companies to players in the market for development of specimen collection kits is boosting the market.
• Wide acceptance of these diagnostic test due to its faster and accurate results during the times of pandemic such coronavirus, Ebola, and others present key driving factors for the market.
• Lack of a strong global supply chain for the specimen collection devices and equipment due to different regulations regarding the transfer and approval of technology act a key challenge that can hamper the market growth.  
• Massive R&D activities to develop innovative technology for the testing and diagnostic are offering immense opportunities for the market expansion.

Scope of Bacterial & Viral Specimen Collection Market Report

The report on the global bacterial & viral specimen collection market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Bacterial & Viral Specimen Collection Market Segment Insights

Bacterial specimen collection segment to dominate the market

Based on products, the global bacterial & viral specimen collection market is bifurcated into bacterial specimen collection and viral specimen collection. The bacterial specimen collection segment is further sub-segmented into swabs, blood collection kits, and other consumables. Similarly, the viral specimen collection segment is also sub-segmented into swabs, viral transport media, blood collection kits, and other consumables. The bacterial specimen collection segment is expected to dominate the market with a high CAGR during the forecast period. The growth of this segment is attributed to the increased prevalence of tuberculosis (TB) as the latent TB remains a major burden affecting about one-quarter of the world's population. The widespread diagnosis of TB has accelerated the use of various bacterial specimen collection materials. However, the viral specimen collection segment is anticipated to grow at a significant rate during the forecast period owing to various advancement in detection of virus infections.

Diagnostics segment to constitute a large revenue share

On the basis of applications, the market is bifurcated into diagnostics and research. The diagnostics segment is expected to constitute a large revenue share of the market during the forecast period. The growth of this segment is attributed to rise in the number of FDA-approved clinical transport media, swabs, and specimen collection kits. The emphasis of government agencies is focusing on the preventing of the transmission of bacterial and viral infections that have potential to become pandemics. As a result, several governments involve in launching a massive campaign to combat tuberculosis, pneumonia, adenovirus, rhinovirus, and coronavirus. All these efforts by government bodies are expected to propel the growth of this segment.

Hospitals & clinics segment to exhibit a rapid CAGR

Based on end-users, the global bacterial & viral specimen collection market is segmented into hospitals & clinics, home test, and research laboratories. The hospitals & clinics segment accounted for a large revenue share of the market owing to increase in the number of patients with respiratory viruses and bacterial infections. As a result, rising demand for antimicrobial drug therapies is expected to boost the market. Furthermore, the use of bacterial and viral specimen collection products in hospitals and clinics are increasing rapidly due to an increase in the number of cases of healthcare-associated infections in acute care hospitals. On the other hand, the home test segment is expected to grow at a fast pace during the forecast period due to the rising availability of home-based diagnostic tests.

North America dominated the market

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market accounting for a key market share in 2020 and is projected to hold a major share in the coming years. In this region, there is a high degree of knowledge about disease transmission, diagnosis, and effective management of microbial infections. As a result, several diagnostic and testing devices are widely used, resulting in a greater revenue share for this region. The investments made by government agencies to promote product production have an additional impact on sales growth. However, the market in Asia Pacific is expected to grow significantly during the forecast period due to wide demand for bacterial and viral specimen collection. Increasing large-scale coronavirus testing in region, particularly in India, due to second-wave of the pandemic presents another key factor driving the regional market.

Segments

The global bacterial & viral specimen collection market has been segmented on the basis of

Products

• Bacterial Specimen Collection
  • Swabs
  • Bacterial Transport Media
  • Blood Collection Kits
  • Other Consumables
• Viral Specimen Collection
  • Swabs
  • Viral Transport Media
  • Blood Collection Kits
  • Other Consumables

Applications

• Diagnostics
• Research

End-users

• Hospitals & Clinics
• Home Test
• Research Laboratories

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Puritan Medical Products
• COPAN Diagnostics
• Becton, Dickinson and Company
• Thermo Fisher Scientific, Inc.
• Quidel Corporation
• Longhorn Vaccines and Diagnostics, LLC
• Pretium Packaging
• Trinity Biotech
• Medical Wire & Equipment
• HiMedia Laboratories
• Hardy Diagnostics
• Nest Scientific
• VIRCELL S.L.
• DiaSorin
• Titan Biotech

Competitive Landscape

Some of the major players competing in the market are Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific, Inc.; Quidel Corporation; Longhorn Vaccines and Diagnostics, LLC; Pretium Packaging; Trinity Biotech; Medical Wire & Equipment; HiMedia Laboratories; Hardy Diagnostics; Nest Scientific; VIRCELL S.L.; DiaSorin; and Titan Biotech.

These companies are collaborating and partnering with a number of domestic and foreign firms to develop bacterial and viral specimen collection products. For instance, in June 2020, Henkel AG & Co. KGaA collaborated with Origin, to take advantage of the latter's expertise in performing rigorous mechanical testing at its California plant. Henkel has contributed several expertise and technologies related to the creation of 3D-printed nasopharyngeal swabs for COVID-19 research. Furthermore, diagnostic firms are pursuing lucrative business strategies to gain a competitive advantage in the area of infectious disease research, resulting in increased demand for specimen collection solutions. For instance, Thermo Fisher partnered with NanoPin Technologies, Inc. in February 2020 to create highly sensitive liquid chromatography-mass spectrometry workflows to advance blood-based infectious disease diagnosis.